AffinityImmuno Inc.

Published purpose

A major roadblock in COVID-19 research is the lack of available reagents for research and manufacturing. The need for research reagents is urgent. AffinityImmuno has developed a very rapid turnaround immunization protocol and has the first available antibodies on the market. AffinityImmuno has raised antibodies against the full extracellular domain of COVID-19 spike protein and nucleocapsid and has the opportunity to develop critical components that will be used in R&D of diagnostic products and products that will affect the disease course. Because the antibodies were raised in chicken we have a large supply and are now working towards developing critical products in partnership with the private sector and academia.